Crystalline Psilocin–Psilocybin Forms for Stability and Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new treatments for mental health disorders and central nervous system disorders, particularly those resistant to current treatments, due to the chemical instability of psilocin and limited clinical studies on its effects compared to psilocybin.
Innovation Solution
Development of crystalline forms of psilocin and psilocybin, characterized by specific XRPD patterns and ratios, which are chemically stable and potentially more effective in treating mental health disorders and CNS conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If psilocin is used alone to treat mental health disorders, then faster absorption and more rapid onset of action are achieved, but chemical instability and rapid oxidation occur
Solution Approach 1:
The patent combines psilocin and psilocybin in a single crystalline formulation, creating a composite material that leverages the rapid absorption properties of psilocin while the psilocybin component provides chemical stability and resistance to oxidation, thus resolving the contradiction between speed and stability
Solution Approach 2:
Psilocybin acts as a stable precursor that can serve as an intermediary, being converted to psilocin in the body, thereby providing a stable delivery mechanism that ultimately releases the active psilocin compound needed for rapid therapeutic effect
2Stability of the object's composition
If psilocybin is used to treat mental health disorders, then chemical stability is maintained, but slower absorption and delayed onset of action occur
Solution Approach 1:
By formulating a crystalline composition containing both psilocybin and psilocin in specific ratios, the patent creates a composite that provides both the stability of psilocybin and the rapid absorption characteristics of psilocin, eliminating the need to choose between stability and speed
Solution Approach 2:
The crystalline formulation is prepared in advance with optimized ratios of psilocybin and psilocin, pre-configuring the composition to achieve both stability during storage and rapid absorption upon administration, eliminating the need for post-manufacturing adjustments
3Reliability
If crystalline forms of psilocin and psilocybin are developed, then chemical stability and therapeutic effectiveness are improved, but manufacturing complexity increases
Solution Approach 1:
The patent identifies and characterizes three distinct crystalline forms (A, B, and C) with specific XRPD patterns, allowing manufacturers to select from defined parameter sets that ensure therapeutic effectiveness while providing clear quality control parameters for manufacturing processes
Solution Approach 2:
The crystalline formulation serves multiple functions simultaneously: it provides chemical stability, ensures rapid absorption, achieves therapeutic effectiveness, and offers distinct XRPD characterization for quality control, thereby reducing overall manufacturing complexity through multi-functionality
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms of psilocin and psilocybin provide a stable and effective treatment option for disorders such as PTSD and depression, offering unique therapeutic benefits through precise chemical compositions.
Implementation Method 1
Crystalline Form A may be characterized by a XRPD pattern comprising a significant peak at a 2θ angle of about 10.1°
Implementation Method 2
A XRPD pattern of crystalline Form A may additionally comprise a significant peak at 2θ angle of about 19.16°
Data Source
AI summary
The present disclosure provides a composition comprising crystalline forms A, B, and C of psilocin and psilocybin. Solvent screen, X-ray powder diffractogram, thermogravimetric mass spectroscopy, differential scanning calorimetry, 1H-NMR, dynamic vapor sorption, and UPLC data on each of the crystalline forms is presented, along with methods preparing each of the crystalline forms.